News

Ophthalmology Times3d
EMA application filed by Bayer to expand aflibercept 8mg indication to include retinal vein occlusion
In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular ...
These are the drugs that lose their U.S. patents in 2025: most are in common use across the country by millions of people
As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for ...
Pharmabiz3d
Bayer seeks EMA approval for aflibercept 8 mg for treatment of retinal vein occlusion
Bayer seeks EMA approval for aflibercept 8 mg for treatment of retinal vein occlusion: Berlin Thursday, April 10, 2025, 16:00 Hrs [IST] Bayer has submitted an application to the E ...
Chosunbiz3d
Celltrion gains Australian approval for three biosimilars in ophthalmology and bone disease
Celltrion gains Australian approval for three biosimilars in ophthalmology and bone disease Celltrion secures TGA endorsement ...
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like ...
Fierce Biotech2d
Opthea lays off 65% of staff after back-to-back phase 3 eye disease flops
Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...
Celltrion wins 3 biosimilar approvals in Australia, eyes Oceania growth
South Korea’s pharmaceutical giant Celltrion said Thursday it has received regulatory approvals for three biosimilars in ...
pharmaphorum5d
After earlier rejection, high-dose Eylea clears FDA
Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...